Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals.

Introduction And Aim: Data on the efficacy and tolerance of interferon-free treatment in chronic hepatitis C (CHC) in elderly patients are limited in phase II-III trials.

Material And Methods: A prospective cohort of adult patients with CHC treated in French general hospitals.

Results: Data from 1,123 patients, distributed into four age groups, were analyzed.

Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH).

Background And Aims: According to clinical trials, the treatment of patients with chronic hepatitis C (CHC) with second-generation direct acting antiviral agents (DAAs) is highly efficient and well tolerated. The goal of this study was to investigate the effectiveness and safety of various combinations of these drugs during their first 2 years of use in the real-world practice of French general hospitals.

Methods: Data from patients treated with all-oral DAAs in 24 French non-academic hospital centers from March 1, 2014 to January 1, 2016, were prospectively recorded.

[Lymphocytic gastritis with anasarca and venous thrombosis].

Introduction: Venous thrombosis has not previously been reported as a complication of lymphocytic gastritis.

Case: A 47-year-old patient was admitted for anasarca related to varioliform gastritis. The densitometric examination showed two partial thromboses, at the confluence of the splenic and mesenteric veins and in the postrenal vena cava.